Mohammad Hadi Sadeghian
Overview
Explore the profile of Mohammad Hadi Sadeghian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
309
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheikhi M, Siyadat P, Rostami M, Sadeghian M, Zahiri E, Ghorbani M, et al.
Caspian J Intern Med
. 2024 Oct;
15(4):579-588.
PMID: 39359452
Background: NUP98 gene fusions in acute myeloid leukemia (AML) have recently attracted much interest. Despite substantial research illuminating the roles of NUP98 fusions in the course of AML, their impacts...
2.
Ghorbani M, Soukhtanloo M, Salek Farrokhi A, Hassanian S, Ghorbani F, Afshari A, et al.
Med Oncol
. 2024 Jul;
41(9):213.
PMID: 39080144
No abstract available.
3.
Mollahoseini Foomani F, Sadeghian M, Bagheri S, Badiee Z, Bazargani R, Aryanpour Z, et al.
Int J Hematol Oncol Stem Cell Res
. 2023 Aug;
17(1):4-8.
PMID: 37638288
Thalassemia is an inherited disease with anemia and hemolysis. Blood transfusion is a routine treatment for thalassemia patients; alloimmunization is one of the complications of blood transfusion, which is very...
4.
Naghinezhad J, Alenabi A, Ayatollahi H, Sheikhi M, Sadeghian M, Khoshnegah Z, et al.
Med J Islam Repub Iran
. 2023 Aug;
37:68.
PMID: 37575689
Background: Acute myeloid leukemia (AML) is the most common acute leukemia in adults and accompanies a worse survival. In this study, gene expression levels of 5 key players of apoptosis,...
5.
Ghorbani M, Soukhtanloo M, Salek Farrokhi A, Hassanian S, Ghorbani F, Afshari A, et al.
Med Oncol
. 2023 Jul;
40(8):231.
PMID: 37432498
Acute myeloid leukemia is one of the most commonly identified hematological malignancies with poor prognosis. This research was planned to identify the cytotoxic effects of Auraptene on HL60 and U937...
6.
Boroumand-Noughabi S, Pashaee A, Montazer M, Rahmati A, Ayatollahi H, Sadeghian M, et al.
J Pediatr Hematol Oncol
. 2023 Jan;
45(5):e603-e608.
PMID: 36706314
Background: The chimeric enzyme SETMAR (or Metnase) has been associated with several DNA processes, including DNA damage repair through the non-homologous joining pathway and suppression of chromosomal translocation in mouse...
7.
Yazdandoust E, Sadeghian M, Shams S, Ayatollahi H, Saadatpour Y, Siyadat P, et al.
Iran J Pathol
. 2022 Dec;
17(4):419-426.
PMID: 36532642
Background & Objective: Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by genetic abnormalities. Currently, molecular and genetic factors are routinely used as diagnostic and prognostic markers. FLT-3 is...
8.
Parsa-Kondelaji M, Ayatollahi H, Rostami M, Sheikhi M, Barzegar F, Afzalaghaee M, et al.
J Cell Mol Med
. 2022 Jun;
26(13):3797-3801.
PMID: 35692075
To evaluate the frequency and prognosis of runt-related transcription factor 1 (RUNX1) and additional sex combs like-1 (ASXL1) mutations in acute myeloid leukaemia (AML) patients in northeastern Iran. This cross-sectional...
9.
Chehreghani Z, Sadeghian M, Ayatollahi H, Bagheri P, Zafari Z, Rezazadeh O, et al.
Asian Pac J Cancer Prev
. 2022 Mar;
23(3):803-806.
PMID: 35345350
Method: Hence, our study was aimed to analyze TET2mut in patients with de-novo AML and their association with clinical, molecular characteristics and Nucleophosmin 1 (NPM1), Fms-like tyrosine kinase 3 (FLT3),...
10.
Jalili-Nik M, Soukhtanloo M, Mojarrad M, Sadeghian M, Mashkani B
Prep Biochem Biotechnol
. 2022 Feb;
52(9):1001-1007.
PMID: 35133942
Tissue factor (TF) is the core reagent in the prothrombin time (PT) assay. In this study, expression and α-factor mediated secretion of three forms of tissue factor (full-length TF (Full-TF),...